by Bile duct cancer, also known as cholangiocarcinoma, is a rare type of cancer that forms in the bile duct. The bile duct cancer drugs market comprises chemotherapy, targeted therapy, and immunotherapy drugs used to treat intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma. Targeted therapy drugs help to block the growth and spread of cancer cells by interfering with specific molecules involved in tumor growth and progression.
The global bile duct cancer market is estimated to be valued at US$ 235.9 Mn in 2023 and is expected to exhibit a CAGR of 5.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing research collaborations is one of the key trends being observed in the bile duct cancer market. Pharmaceutical companies are collaborating with research institutes and hospitals to develop advanced treatment options and diagnostic tools for bile duct cancer. For instance, in September 2021, Agalimmune Ltd., a UK-based biotechnology company developing antifibrotic therapies in diseases with significant fibrosis, announced a research collaboration with the Christie NHS Foundation Trust, a cancer treatment and research center in Manchester, UK, to identify biomarkers for the progression of cholangiocarcinoma. Such initiatives are helping boost research activities in bile duct cancer treatment, thus driving market growth over the forecast period.
Segment Analysis
The global bile duct cancer market is dominated by the intrahepatic bile duct cancer sub-segment, which accounted for nearly 60% share of the overall market in 2023. This is because intrahepatic bile duct cancer originates in the bile ducts inside the liver and is more common than other types of bile duct cancers. Early symptoms of this type of cancer are often vague and non-specific, leading to delays in diagnosis and more advanced disease at the time of treatment.
Key Takeaways
The Global Bile Duct Cancer Market Demand is expected to witness high growth over the forecast period of 2023 to 2030. Being an orphan cancer with low incidence rates, the overall bile duct cancer market is currently small. However, increasing risk factors like primary sclerosing cholangitis are expected to drive market growth going forward. The global bile duct cancer market is estimated to be valued at US$ 235.9 Mn in 2023 and is expected to exhibit a CAGR of 5.5% over the forecast period 2023 to 2030.
Regional analysis
Europe accounted for the largest share of over 35% in the global bile duct cancer market in 2023 due to higher incidence and early adoption of advanced therapies. However, Asia Pacific region is expected to grow at the fastest pace during the forecast period supported by rising healthcare expenditures, growing awareness, and improving access to advanced treatment options in major countries like China and India.
Key players operating in the bile duct cancer market are Biffa Plc, Clean Harbors, Inc., Covanta Holding Corporation, Daiseki Co., Ltd, Hitachi Zosen Corporation, Remondis Se & Co. Kg, Republic Services, Inc., Suez, Veolia Environment, and Waste Management Inc. Hitachi Zosen Corporation is a dominant player in bile duct cancer diagnostics and screening services while Biffa Plc leads in targeted therapy segments.
Note:
Source: Coherent Market Insights, Public sources, Desk research
We have leveraged AI tools to mine information and compile it
